ALXA News 3.58 08/14/2014 04:31:27 Alexza Pharmaceuticals (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexza Pharmaceuticals (ALXA) 3.58 $ALXA

Alexza Pharmaceuticals unveils ADASUVE in Guatemala for schizophrenia or bipolar disorder, reflecting ADASUVE 's first approval in a Latin American country
M2 - Mon Aug 11, 7:22AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Friday announced the market availability of ADASUVE inhalation powder, pre-dispensed (loxapine) in Guatemala for treating schizophrenia or bipolar disorder, representing the first ADASUVE approval in Latin America.

Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in Guatemala
PR Newswire - Fri Aug 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries.

Downgrade Alert for Alexza Pharmaceuticals (ALXA)
Comtex SmarTrend(R) - Fri Aug 08, 7:10AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $4.86 on volume of 66,000 shares, below average daily volume of 121,000. Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions.

Alexza's net loss widens to USD6.0m in Q2 2014
M2 - Fri Aug 08, 6:43AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Thursday disclosed a net loss of USD6.0m for the quarter ended 30 June 2014.

Alexza Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2014. The net loss for the second quarter was $6.0 million compared to $0.8 million during the same quarter in 2013. During the three months ended June 30, 2013, Alexza recognized $42.8 million in licensing revenue associated with the signing of the Company's License and Supply Agreement with Teva Pharmaceuticals USA, Inc. The net loss for the six months ended June 30, 2014 and 2013 was $16.7 million and $21.5 million, respectively. At June 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $49.2 million.

Alexza Provides Pipeline Update
PR Newswire - Thu Jul 31, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease (PD) patients.

Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
PR Newswire - Tue Jul 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below:

Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
PR Newswire - Thu Jul 17, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures

Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs
PR Newswire - Mon Jun 30, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.

Alexza Pharmaceuticals closes private placement of USD45m non-recourse notes
M2 - Thu Mar 20, 7:57AM CDT
Central nervous system treatment company Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the completion of a private placement of USD45.0m of non-recourse notes to institutional investors.

Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes
PR Newswire - Wed Mar 19, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes" . The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE® (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S. is Teva Pharmaceuticals USA, Inc.

Alexza Pharmaceuticals and Ferrer Announce the Launch of ADASUVE® (inhalation powder, loxapine) in Romania
PR Newswire - Thu Mar 13, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A.

Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.

Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.

Alexza Pharmaceuticals' Corporate Presentation to be Webcast from Two Upcoming March Investor Conferences
PR Newswire - Thu Feb 20, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:

Alexza to Report 2013 Year-End Financial Results on Thursday, March 6, 2014
PR Newswire - Thu Feb 13, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31, 2013 on Thursday, March 6, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 103

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 0

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 188

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 190

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 27

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 8

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Disclosure on Rathbones Group and De La Rue Plc

Updated Category News Views 144

Key Public Position Disclosure for Rathbones Group Plc Understanding the dynamics behind stock holding and market behavior is crucial for investors and stakeholders. This article sheds light on the recent public opening position disclosure made by Rathbones Group Plc regarding its interests in De La Rue Plc. According to the regulations of the Takeover Code, disclosers...

Continue Reading
ThinkAndor® Reigns as Leading AI Platform for Virtual Care

Updated Category News Views 132

ThinkAndor® Wins Top Honors in Virtual Care Solutions Andor Health's ThinkAndor® has distinguished itself yet again as the leading **AI healthcare software infrastructure**, confirmed by recent evaluations as the best virtual care platform. This notable recognition by an acclaimed market research assessment underscores the platform's unmatched capabilities in bringing...

Continue Reading
Jayud Global Logistics: Legal Actions and Investment Alerts

Updated Category News Views 165

Understanding the Securities Fraud Class Action Against Jayud The Law Offices of Howard G. Smith have announced a significant legal development involving Jayud Global Logistics Limited (NASDAQ: JYD). A class action lawsuit has been initiated on behalf of investors who purchased Jayud securities. The lawsuit covers shares bought during a specific period, and affected...

Continue Reading
Exploring the Explosive Growth of the 3D Printing Market

Updated Category News Views 101

3D Printing Market Size Analysis As of 2023, the 3D printing market was valued at USD 21.1 billion and is expected to grow to USD 118.9 billion by 2032, reflecting a compound annual growth rate (CAGR) of 21.2% during the forecast period. Current Trends Fueling Growth The 3D printing industry is experiencing remarkable expansion, driven by technological innovations and...

Continue Reading
Nexus Industrial REIT Sells Legacy Properties and Expands Operations

Updated Category News Views 111

Nexus Industrial REIT Emphasizes Focus on Industrial Real Estate Nexus Industrial REIT is creating a buzz in the market with its recent strategic initiatives. The company has officially offloaded a 50% stake in six office buildings, reinforcing its concentration on industrial properties. This transaction signifies a key moment, bolstering Nexus's standing as a prominent...

Continue Reading